{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:58:39Z","timestamp":1772585919009,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15611-4","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:23:42Z","timestamp":1770107022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns and clinical outcomes in chemotherapy-treated patients with HR+\/HER2\u2212 metastatic breast cancer using real-world data in France and Germany"],"prefix":"10.1186","volume":"26","author":[{"given":"Mario","family":"Campone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Sebastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena I. I.","family":"Kiver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Woeckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1tia","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria M.","family":"Saglimbene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quratul","family":"Ann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Sadetsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikoleta","family":"Sjekloca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Libert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Bocquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"15611_CR1","unstructured":"DePolo J. Types of breast cancer - metastatic breast cancer: breastcancer.org; 2024. https:\/\/www.breastcancer.org\/types\/metastatic. Accessed 13 Dec 2024."},{"issue":"12","key":"15611_CR2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. Esmo clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"15611_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","volume":"157","author":"T Dyba","year":"2021","unstructured":"Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2021.07.039.","journal-title":"Eur J Cancer"},{"issue":"12","key":"15611_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/jco.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366. https:\/\/doi.org\/10.1200\/jco.19.02309.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15611_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41416-020-0979-3","volume":"123","author":"J Simon","year":"2020","unstructured":"Simon J, Chaix M, Billa O, Kamga AM, Roignot P, Ladoire S, et al. Survival in patients with HR+\/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study. Br J Cancer. 2020;123(7):1071\u20137. https:\/\/doi.org\/10.1038\/s41416-020-0979-3.","journal-title":"Br J Cancer"},{"issue":"4","key":"15611_CR6","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/j.clbc.2017.10.008","volume":"18","author":"SK Kurosky","year":"2018","unstructured":"Kurosky SK, Mitra D, Zanotti G, Kaye JA. Treatment patterns and outcomes of patients with metastatic ER(+)\/HER-2(-) breast cancer: a multicountry retrospective medical record review. Clin Breast Cancer. 2018;18(4):e529\u201338. https:\/\/doi.org\/10.1016\/j.clbc.2017.10.008.","journal-title":"Clin Breast Cancer"},{"key":"15611_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ctrv.2017.12.002","volume":"63","author":"GA Ba\u015faran","year":"2018","unstructured":"Ba\u015faran GA, Twelves C, Di\u00e9ras V, Cort\u00e9s J, Awada A. Ongoing unmet needs in treating estrogen receptor-positive\/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018;63:144\u201355. https:\/\/doi.org\/10.1016\/j.ctrv.2017.12.002.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"15611_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdz012.","journal-title":"Ann Oncol"},{"issue":"9769","key":"15611_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(11)60070-6.","journal-title":"Lancet"},{"key":"15611_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer. 2019;112:57\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2019.02.002.","journal-title":"Eur J Cancer"},{"issue":"1","key":"15611_CR11","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.clbc.2014.09.001","volume":"15","author":"IH Park","year":"2015","unstructured":"Park IH, Lee KS, Ro J. Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2015;15(1):e55-62. https:\/\/doi.org\/10.1016\/j.clbc.2014.09.001.","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"15611_CR12","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/jjco\/hyab131","volume":"51","author":"M Hattori","year":"2021","unstructured":"Hattori M, Novick D, Takaura K, Tanizawa Y, Kawaguchi T, Haro JM, et al. A systematic literature review of prognostic factors in patients with HR+\/HER2- advanced breast cancer in Japan. Jpn J Clin Oncol. 2021;51(10):1498\u2013508.","journal-title":"Jpn J Clin Oncol"},{"key":"15611_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4137\/bcbcr.S39615","volume":"10","author":"C Twelves","year":"2016","unstructured":"Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl). 2016;10:77\u201384. https:\/\/doi.org\/10.4137\/bcbcr.S39615.","journal-title":"Breast Cancer (Auckl)"},{"issue":"9","key":"15611_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103691","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Punie K, Carey LA, Kurian AW, Ntalla I, Sjekloca N, et al. Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States. ESMO Open. 2024;9(9):103691. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103691.","journal-title":"ESMO Open"},{"issue":"10","key":"15611_CR15","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674\u201389. https:\/\/doi.org\/10.1016\/S2666-7568(22)00186-6.","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"15611_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-020-05838-5","volume":"184","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O\u2019Shaughnessy J, et al. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat. 2020;184(1):161\u201372. https:\/\/doi.org\/10.1007\/s10549-020-05838-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"15611_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-020-05867-0","volume":"184","author":"S Kazmi","year":"2020","unstructured":"Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat. 2020;184(2):559\u201365. https:\/\/doi.org\/10.1007\/s10549-020-05867-0.","journal-title":"Breast Cancer Res Treat"},{"key":"15611_CR18","unstructured":"Eurostat. Demography of Europe \u2013 2024 edition 2024. https:\/\/ec.europa.eu\/eurostat\/web\/interactive-publications\/demography-2024. Accessed 5 Feb 2025."},{"issue":"1","key":"15611_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02754-5","volume":"21","author":"C Courtinard","year":"2023","unstructured":"Courtinard C, Gourgou S, Jacot W, Carton M, Gu\u00e9rin O, Vacher L, et al. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database. BMC Med. 2023;21(1):87. https:\/\/doi.org\/10.1186\/s12916-023-02754-5.","journal-title":"BMC Med"},{"issue":"10","key":"15611_CR20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1055\/a-1880-0087","volume":"82","author":"T Engler","year":"2022","unstructured":"Engler T, Fasching PA, L\u00fcftner D, Hartkopf AD, M\u00fcller V, Kolberg HC, et al. Implementation of CDK4\/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients - data from the real-world registry PRAEGNANT. Geburtshilfe Frauenheilkd. 2022;82(10):1055\u201367.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"12","key":"15611_CR21","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O\u2019Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709\u201318. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.004.","journal-title":"Ann Oncol"},{"key":"15611_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.03.013","volume":"95","author":"E Jacquet","year":"2018","unstructured":"Jacquet E, Lardy-Cl\u00e9aud A, Pistilli B, Franck S, Cottu P, Delaloge S, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer. 2018;95:93\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2018.03.013.","journal-title":"Eur J Cancer"},{"key":"15611_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2019.06.014","volume":"118","author":"O Le Saux","year":"2019","unstructured":"Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, et al. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Eur J Cancer. 2019;118:131\u201341. https:\/\/doi.org\/10.1016\/j.ejca.2019.06.014.","journal-title":"Eur J Cancer"},{"key":"15611_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103866","volume":"180","author":"C Vieira","year":"2022","unstructured":"Vieira C, Piperis MN, Sagkriotis A, Cottu P. Systemic treatment for hormone receptor-positive\/HER2-negative advanced\/metastatic breast cancer: a review of European real-world evidence studies. Crit Rev Oncol Hematol. 2022;180:103866. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103866.","journal-title":"Crit Rev Oncol Hematol"},{"key":"15611_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.breast.2017.10.002","volume":"37","author":"AD Hartkopf","year":"2018","unstructured":"Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - data from the German PRAEGNANT breast cancer registry. Breast. 2018;37:42\u201351. https:\/\/doi.org\/10.1016\/j.breast.2017.10.002.","journal-title":"Breast"},{"key":"15611_CR26","unstructured":"Institut I. Reimbursement of pharmaceuticals in Germany. https:\/\/www.iges.com\/e15094\/e15095\/e15096\/e17469\/IGES_Reimbursement_Pharmaceuticals_Germany_2020_2021_WEB_ger.pdf. Accessed 5 Feb 2025."},{"issue":"12","key":"15611_CR27","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol"},{"issue":"4","key":"15611_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100204","volume":"6","author":"E Adams","year":"2021","unstructured":"Adams E, Wildiers H, Neven P, Punie K. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. ESMO Open. 2021;6(4):100204. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100204.","journal-title":"ESMO Open"},{"key":"15611_CR29","unstructured":"Sciences. G. Phase 3 study of sacituzumab govitecan (IMMU-132) versus Treatment of Physician\u2019s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens. Report No.: NCT03901339: clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03901339. Accessed on 5 Feb 2025."},{"key":"15611_CR30","unstructured":"Daiichi Sankyo I. A Phase 3, multicenter, randomized, open-label, active controlled trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), versus treatment of physician\u2019s choice for her2-low, unresectable and\/or metastatic breast cancer subjects. Report No. NCT03734029: clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03734029. Accessed on 5 Feb 2025."},{"issue":"1","key":"15611_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"issue":"22","key":"15611_CR32","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"},{"issue":"10411","key":"15611_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X.","journal-title":"Lancet"},{"key":"15611_CR34","doi-asserted-by":"crossref","unstructured":"Pistilli B, Jhaveri K, Im SA, Pernas Simon S, De Laurentiis M, Wang S, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial. ESMO Virtual Plenary; 2025. VP1\u20132025.","DOI":"10.1016\/j.annonc.2025.01.009"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15611-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:08:14Z","timestamp":1772582894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15611-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15611"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15611-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki and was approved by the Ethics Commissions of the Angers University Hospital Center (CHU Angers) in France and the Julius-Maximilians University of W\u00fcrzburg (JMU) in Germany. This retrospective, observational study used de-identified data from an existing dataset of electronic health record data, did not involve direct enrolment of patients and personal identifiable data were not collected; the research team did not have a role in the initial collection of the data with identifiers and did not have access to identifiers. Therefore, no informed consent or waiver was required in accordance with EU General Data Protection Regulations (GDPR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC has received honoraria for presentations from Eli Lilly and Novartis, travel support from AstraZeneca, Novartis and Pfizer, and has participated in data safety monitoring or advisory boards for AstraZeneca, Daichi-Sankyo, Eli Lilly, Gilead, Menarini, Novartis, Sanofi and Seagen. JSF has received consulting fees, honoraria for presentations, travel support and has participated in data safety monitoring or advisory boards for AstraZeneca, Daichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, MSD, Novartis, Pfizer and Seagen. VIIK has received consultancy fees for advisory boards and round tables from Eli Lilly, Gilead, Novartis and Pfizer, honoraria for presentations from AstraZeneca, Eisai, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche and Seagen, travel support from Gilead and Novartis, research support from Novartis, and funding from Gilead for participation in this study. AW has served on advisory boards for AstraZeneca, MSD, Pfizer, Roche, Stemline and Novartis and has been an invited speaker for Daichi-Sankyo, Gilead, Eli Lilly, Novartis, and Pfizer. AGK has financial interests in Janssen and has received consultancy fees from IQVIA. MK has served on advisory boards for Janssen and GSK Oncology and has received consultancy fees from IQVIA. FB has been involved in advisory boards for Roche. CL, VMS, and QA are employees of IQVIA. IQVIA received funding from Gilead for the running of the study. NS, NS, OL and AK are employees of Gilead.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}